Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
A phase 3 trial of Apalutamide, Degarelix, Fluciclovine F-18, Goserelin / leuprolide, Leuprolide, Relugolix and Triptorelin in Prostate cancer, run by ECOG-ACRIN Cancer Research Group, now recruiting.
Overview
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging is a phase 3 interventional study registered as NCT04423211 by ECOG-ACRIN Cancer Research Group, with 804 participants planned, started 2020-10-08 and due to reach its primary completion in 2032-12-31. Interventions recorded: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy. Conditions recorded: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8.
Linked to the drug Fluciclovine F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Shares Relugolix, Degarelix, Triptorelin, Goserelin / leuprolide (ovarian function suppression) and the tag pipeline.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Relugolix, Degarelix, Triptorelin, Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.
- TrialRadiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Shares Degarelix, Triptorelin, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Shares Degarelix, Triptorelin, Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists and the tag pipeline.
- TrialFlutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Shares Goserelin / leuprolide (ovarian function suppression), Leuprolide (leuprorelin) and GnRH agonists, Prostate cancer and the tag pipeline.
- TrialNeoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Shares Degarelix, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialInvestigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Shares Degarelix, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.
- TrialProstate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Shares Triptorelin, Goserelin / leuprolide (ovarian function suppression), Prostate cancer and the tag pipeline.